Perspective Therapeutics (CATX) Cash from Financing Activities (2010 - 2026)

Perspective Therapeutics has disclosed Cash from Financing Activities across 16 years of filings, most recently posting $164.4 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $164.4 million, up 1548.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $164.7 million (up 23.8% YoY), and the FY2025 annual result was $10.3 million, down 96.44% from the prior year.
• Cash from Financing Activities came in at $164.4 million for Q1 2026 at Perspective Therapeutics, up from -$13000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $166.3 million in Q1 2024 to a low of -$80000.0 in Q1 2023.
• The 5-year median for Cash from Financing Activities is $345000.0 (2024), against an average of $31.0 million.
• Across the five-year window, Cash from Financing Activities surged 208010.0% in 2024 and sank 103.77% in 2025, its largest moves.
• Perspective Therapeutics' Cash from Financing Activities stood at $28000.0 in 2022, then soared by 1157.14% to $352000.0 in 2023, then retreated by 1.99% to $345000.0 in 2024, then tumbled by 103.77% to -$13000.0 in 2025, then soared by 1264438.46% to $164.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $164.4 million (Q1 2026), -$13000.0 (Q4 2025), and $213000.0 (Q3 2025), per Business Quant data.